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I.  INTRODUCTION 
 
Cancer-related mortality is the second major cause of death, posing as a significant 
public health burden worldwide. In 2012, cancer accounted for 8.2 million deaths and 14.1 
million new cancer cases across the globe, while 32.6 million people entered the period of 5-
year remission (partial or complete). Among the EU member states, the incidence of lung and 
colon cancers and the mortality associated with these tumors is the highest in Hungary. Cancer 
refers to a broad group of diseases characterized by the conversion of healthy cells into 
malignant cells that are able to divide and grow uncontrollably, becoming a danger to the 
integrity of the rest of the organism. The causative agents of malignant disorders include genetic 
predisposition, lifestyle choices, environmental factors and other factors, such as 
immunosuppression and various medicinal drugs leading to the development of neoplasms.  
The main objective of cancer treatment is the elimination of all tumor cells present in 
the patient’s body. The three most commonly utilized strategies for the treatment of cancer are 
the following: surgery, radiotherapy and chemotherapy, which can be either used alone or in 
combination. Chemotherapy is the most frequently used method, both for hematological 
malignancies and solid tumors. The phenomenon whereby tumors show resistance to 
chemotherapeutic agents of different structure and mechanism of action is termed multidrug 
resistance (MDR), which can be mediated by a variety of mechanisms. For the purposes of this 
thesis, the importance of efflux pump-mediated MDR and the deficiencies in apoptosis 
induction of cancer cells are highlighted. The ATP-binding cassette (ABC) transporter 
superfamily is an extremely important and prevalent group of transport proteins in the human 
body, which bind and hydrolyze ATP to provide the energy needed to transport various 
substrates across the cell membranes. The first characterized ABC transporter was ABCB1, and 
the overexpression of this protein is often associated disadvantageous clinical outcome. Due to 
the flexible and non-specific substrate binding site of this transporter, it can expel a wide variety 
of chemotherapeutic agents. An emerging research approach and therapeutic strategy is to use 
efflux pump inhibitors (EPIs) as adjuvant compounds (so-called ‘chemosensitizers’) to improve 
the efficacy of standard antitumor therapy. One of the most important forms of cell death 
induced by antitumor chemotherapy is apoptosis, and MDR is a scenario where the apoptotic 
processes are defective, resulting in therapy refractory malignancy. 
Many selenoderivatives, both organic and inorganic, have been studied as cancer 
chemopreventive agents and/or as cytotoxic compounds for tumor cells and these results are 
supported by epidemiological trials. The rationale behind the notion of Se-compounds as cancer 
therapeutic agents is associated with their redox modulating activity. Literature suggests that 
cancer cells are more vulnerable to exogenous oxidative stress than healthy, non-tumoral cells, 
because of increased levels of reactive oxygen species (ROS) and a maximum threshold for 
antioxidant capacity, due to the accelerated metabolism of these cells, contributing to successive 
cell division and proliferation. Initially, experimental studies tested inorganic selenium 
compounds for their cytotoxicity and their potential for enhancing the efficacy of chemotherapy 
as adjuvants, however, successive investigations discovered that organoselenium derivatives 
presented with superior biological activities and with less toxicity. These compounds were 
tested in a wide range of in vitro cancer cells model systems and in animal experiments, 
exhibiting potent anticancer and ROS-modulating properties, both as singular agents and in 
combination chemotherapy with clinically relevant anticancer drugs.  
II.  AIMS OF THE STUDY 
 
The aim of our study was to evaluate the activity of novel organoselenium compounds 
synthesized by Domínguez-Álvarez et al. to find effective and selective anticancer derivatives 
using various cell lines (cell lines of murine and human origin, tumoral and non-cancerous cell 
lines) as in vitro model systems. In addition to their cytotoxic activity, their potency as 
multidrug resistance reversing compounds was studied against two resistance mechanisms 
namely inhibition of ABCB1-related efflux and induction of apoptosis in tumor model systems. 
Furthermore, their attributes as potential lead compounds for further derivatization and their 
potential for future in vivo use were also investigated. 
 
The specific goals of the study were the following: 
1. Determination of the cytotoxic activity and selectivity of the compounds (a cyclic 
selenoanhydride, ten selenoesters and four inorganic chalcogen cyanates) on L5178Y 
parental (PAR) and ABCB1-transfected resistant (MDR) mouse T-cell lymphoma cell lines, 
Colo 205 (doxorubicin-sensitive) and resistant Colo 320 (ABCB1-overexpressing) human 
colonic adenocarcinoma cell lines, A549 human lung adenocarcinoma cells, NIH/3T3 
mouse embryonic fibroblast, and MRC-5 human embryonic lung fibroblast cell lines by 
MTT method.  
2. Evaluation of the efflux pump modulatory activity of the compounds (a cyclic 
selenoanhydride, ten selenoesters and four inorganic chalcogen cyanates) on L5178Y 
parental (PAR) and ABCB1-transfected resistant (MDR) mouse T-cell lymphoma cell lines, 
Colo 205 (doxorubicin-sensitive) and resistant Colo 320 (ABCB1-overexpressing) human 
colonic adenocarcinoma cell lines using a flow cytometry-based rhodamine 123 retention 
assay. 
3. Characterization of the selenocompounds (a cyclic selenoanhydride, ten selenoesters and 
four inorganic chalcogen cyanates) as apoptosis inducers using Annexin V-FITC detection 
system on L5178Y parental (PAR) and ABCB1-transfected MDR mouse T-cell lymphoma 
cell lines and resistant Colo 320 (ABCB1-overexpressing) human colonic adenocarcinoma 
cell line. 
4. In silico analysis of predicted physico-chemical and in vivo absorption properties of 
the compounds using OSIRIS Molecular Property Explorer and PreADMET 2.0 software. 
Correlation-regression analysis to study the relationship between the predicted physico-
chemical properties of the selenocompounds and their activity as efflux pump inhibitors.  
5. Determination of structure-activity relationships (SAR) of the selenocompounds based 
on experimental results. 
  
III.  MATERIALS AND METHODS 
 
Compounds 
The tested compounds include a cyclic selenoanhydride (1) and selenoesters (2-11) with 
various functional groups (2-5: methyl group; 6: amide; 7-8: carboxylic ester; 9-11: ketone). 
The synthesis of the compounds was described previously by Domínguez-Álvarez et al. The 
stock solutions (in 10 mM concentration) of the compounds were prepared in DMSO. Phthalic 
anhydride (12; the oxygen isoster of compound 1) and three inorganic chalcogen cyanates (13-
15; 13-KOCN, 14-NH4SCN, 15-KSeCN) were included in the study (Sigma) and used as 
references in our experiments. The following compounds were used during the assays as 
reagents: rhodamine 123 (R123; Sigma, St. Louis, MO, USA), 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT; Sigma, St Louis, MO, USA), sodium dodecyl sulfate 
(SDS; Sigma), verapamil (EGIS Hungarian Pharmaceutical Company, Budapest, Hungary), 
cisplatin (TEVA Pharmaceutical Company, Petah Tikva, Israel) and dimethyl sulfoxide 
(DMSO; Sigma). All the chemical compounds used in the apoptosis assay, except for the 
positive control M627 (12H-benzo[α]phenothiazine) were included in the Annexin V-FITC 
Apoptosis Detection Kit Cat. No. PF 032, purchased from Calbiochem (EMD Biosciences, Inc. 
La Jolla, CA). The positive control M627 was kindly provided by Prof. Dr. Noboru Motohashi 
(Meiji Pharmaceutical University, Kiyose, Tokyo, Japan) and dissolved in DMSO. Stock 
solution of R123 was prepared in PBS and verapamil was dissolved in water. All solutions were 
prepared on the day of assay. 
Cell lines 
L5178Y mouse T-cell lymphoma cells (PAR) (ECACC Cat. No. 87111908, obtained from 
FDA, Silver Spring, MD, USA) were transfected with pHa MDR1/A retrovirus, as previously 
described by Cornwell et al. The ABCB1-expressing cell line (MDR) was selected by 
culturing the infected cells with colchicine. Human colonic adenocarcinoma cell lines (Colo 
205 doxorubicin-sensitive and Colo 320/MDR-LRP multidrug resistant, overexpressing 
ABCB1 (MDR1)-LRP), ATCC-CCL-220.1 (Colo 320) and CCL-222 (Colo 205), A549 human 
lung adenocarcinoma cell line (ATCC CCL-185), NIH/3T3 mouse embryonic fibroblast 
cell line (ATCC CRL-1658) and MRC-5 human embryonic lung fibroblast cell line (ATCC 
CCL-171) were purchased from LGC Promochem, Teddington, UK.  
The L5178Y mouse T-cell lymphoma cells (PAR and MDR) were cultured in McCoy’s 5A 
medium (Sigma-Aldrich, St Louis, MO, USA supplemented with 10% heat-inactivated horse 
serum (Sigma-Aldrich, St Louis, MO, USA), 200 mM L-glutamine (Sigma-Aldrich, St Louis, 
MO, USA), nystatin (Sigma-Aldrich, St Louis, MO, USA) and a penicillin-streptomycin 
mixture (Sigma-Aldrich, St Louis, MO, USA) in concentrations of 100 U/L and 10 mg/L, 
respectively. The human colonic adenocarcinoma cell lines (Colo 205 and Colo 320) were 
cultured in RPMI-1640 medium supplemented with 10% heat-inactivated foetal bovine serum 
(FBS), 2 mM L-glutamine (Sigma-Aldrich, St Louis, MO, USA), 1 mM Na-pyruvate (Sigma-
Aldrich, St Louis, MO, USA), 100 mM HEPES (Sigma-Aldrich, St Louis, MO, USA), nystatin 
(Sigma-Aldrich, St Louis, MO, USA) and a penicillin-streptomycin mixture (Sigma-Aldrich, 
St Louis, MO, USA) in concentrations of 100 U/L and 10 mg/L, respectively. The NIH/3T3 
mouse embryonic fibroblast cell line was cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM; Gibco Life Technologies Co., UK), containing 4.5 g/L glucose, supplemented with 
10% heat-inactivated foetal bovine serum (FBS), 2 mM L-glutamine (Sigma-Aldrich, St Louis, 
MO, USA), 1 mM Na-pyruvate (Sigma-Aldrich, St Louis, MO, USA), nystatin (Sigma-Aldrich, 
St Louis, MO, USA) and a penicillin-streptomycin mixture (Sigma-Aldrich, St Louis, MO, 
USA) in concentrations of 100 U/L and 10 mg/L, respectively. MRC-5 human embryonic 
lung fibroblast cell line and A549 human lung adenocarcinoma cell lines were cultured in 
Eagle’s Minimal Essential Medium (EMEM, Sigma-Aldrich, St Louis, MO, USA) 
supplemented with 1% of non-essential amino acid (NEAA) mixture (Sigma-Aldrich, St Louis, 
MO, USA), a selection of vitamins (in case of the MRC-5 cell line), 10% heat-inactivated foetal 
bovine serum (FBS), 2 mM L-glutamine (Sigma-Aldrich, St Louis, MO, USA), 1 mM Na-
pyruvate (Sigma-Aldrich, St Louis, MO, USA), nystatin (Sigma-Aldrich, St Louis, MO, USA) 
and a penicillin-streptomycin mixture (Sigma-Aldrich, St Louis, MO, USA) in concentrations 
of 100 U/L and 10 mg/L, respectively. 
Assay for cytotoxic effect 
The effects of increasing concentrations of the compounds on cell growth were tested 
in 96-well flat-bottomed microtiter plates. The two-fold serial dilutions of the tested compounds 
were made starting in the third row of the 96-well microtiter plate (4 μL of the 10 mM stock 
solutions were added to 196 μL of medium, then diluted in the respective wells). Then, 104 of 
mouse T-cell lymphoma and human colonic adenocarcinoma cells in 100 μL of the 
corresponding medium were added to each well, except for the medium control wells, resulting 
in a final concentration of 100 μM. The adherent mouse embryonic fibroblast cells (104/well), 
human lung fibroblast cells (1,5×104/well) and human lung adenocarcinoma cells (104/well) 
were seeded in the corresponding medium in 96-well flat-bottomed microtiter plates for 4 hours 
before the assay. The serial dilutions of the compounds were made in a separate plate, and then 
transferred to the plates containing the adherent corresponding cell line. Culture plates were 
incubated at 37˚C for 24 h; at the end of the incubation period, 20 μL of MTT (thiazolyl blue 
tetrazolium bromide, Sigma) solution (from a 5 mg/mL stock solution) were added to each well. 
After incubation at 37˚C for 4 h, 100 μL of sodium dodecyl sulfate (SDS) (Sigma) solution 
(10% SDS in 0.01 M HCl) were added to each well and the plates were further incubated at 
37˚C overnight. Cell growth was determined by measuring the optical density (OD) at 550 nm 
(ref. 630 nm) with Multiscan EX ELISA reader (Thermo Labsystems, Cheshire, WA, USA). 
Inhibition of cell growth was expressed as IC50 values, defined as the inhibitory dose that 
reduces the growth of the cells exposed to the tested compounds by 50%, determined according 
to the formula below: 












Selectivity indices (SI) were calculated to determine the potency of the tested compounds 
towards the tumoral and non-malignant cell lines, respectively. The SI values were calculated 
as a quotient of the IC50 values in the non-tumoral cells divided by the IC50 values in the 
(sensitive or MDR, where applicable) cancer cell lines. The compounds are considered as 
strongly selective if the SI values are higher than 6, moderately selective if 3 < SI < 6, slightly 
selective if 1 < SI < 3 and non-selective if the SI values are lower than 1. 
Assay for the inhibition of the ABCB1 efflux pump 
The inhibition of the cancer multidrug efflux pump ABCB1 by the tested compounds was 
evaluated using flow cytometry, measuring the retention of rhodamine 123 by ABCB1 (P-
glycoprotein) in MDR mouse T-lymphoma cells and Colo320 colonic adenocarcinoma cells, 
as both cell lines overexpress the ABCB1 transporter (P-glycoprotein). This method is a 
fluorescence-based detection system which uses verapamil (a first-generation, competitive 
EPI) as reference inhibitor. Briefly, cell number of mouse T-lymphoma and colonic 
adenocarcinoma cells were adjusted to 2×106 cells/mL, re-suspended in serum-free McCoy’s 
5A medium in case of mouse T-lymphoma cells and serum-free RPMI-1640 medium in case 
of colonic adenocarcinoma cells and distributed in 0.5 mL aliquots into Eppendorf centrifuge 
tubes. The tested compounds were added at different concentrations (2 and 20 µM; from 1 and 
10 mM stock solutions, respectively) and the samples were incubated for 10 minutes at room 
temperature. Verapamil (EGIS Hungarian Pharmaceutical Company, Budapest, Hungary) was 
applied as positive control (20 µM final concentration) and DMSO was used as solvent control 
(at 2 V/V%). Next, 10 µL (5.2 µM final concentration) of the fluorochrome rhodamine 123 
(Sigma, St. Louis, MO, USA) was added to the samples and the cells were incubated for 20 
minutes at 37˚C.  
Rhodamine 123 (R123) is a non-toxic, lipophilic, cationic fluorescent dye  
(λex/em = 505/534 nm), which is a substrate of the ABCB1 transporter. As the compound is 
membrane-permeable, it is rapidly taken up by the cells, therefore it can be effectively used 
for the screening of efflux pump inhibiting compounds. After the incubation period, the cells 
were washed twice and re-suspended in 0.5 mL PBS for analysis. The fluorescence of the 
gated cell population was measured with a Partec CyFlow® flow cytometer (Partec, Münster, 
Germany). The percentage of mean fluorescence intensity was calculated for the treated MDR 
cells as compared with the untreated cells. The results were obtained from a representative 
flow cytometry experiment in which at least 20,000 individual cells of the overall population 
were evaluated for the rhodamine 123 retained inside the cells. The fluorescence activity ratio 






FAR =   
Parameters evaluated from flow cytometric experiments were: Forward Scatter Count (FSC, 
provides information about cell size); Side Scatter Count (SSC, proportional to cell granularity 
or internal complexity); FL-1 (Mean fluorescence of the cells) and Fluorescence Activity Ratio 
(FAR), which was calculated by the equation given above. The efflux pump inhibitory activity 
of the tested compounds was compared to the activity of verapamil, additionally, a FAR-
quotient was calculated, according to the following equation: 
Quotient = 100 x (FARcompound/FARverapamil)   
Assay for apoptosis induction 
The capacity of the selenocompounds to induce apoptosis was investigated by using 
L5178Y mouse T-cell lymphoma cells (parental and ABCB1-transfected) as well as multidrug 
resistant (MDR) Colo 320 colonic adenocarcinoma cells as in vitro model systems. The 
apoptosis induction assays were performed using Annexin V-FITC Apoptosis Detection Kit, 
following the manufacturer’s instructions. This method enables the quantification and 
differentiation of early and late apoptotic events as well as necrosis and cell death in the cell 
population exposed to the respective selenocompounds. In the assay, Annexin V was used as 
phospholipid binding protein, to which fluorescein isothiocyanate (FITC) was conjugated as 
a fluorescent substrate (λex/em=495/519 nm). Because the Annexin-FITC conjugate also binds 
to the externalized phosphatidyl serine of the necrotic cells, propidium iodide (PI; 
λex/em=535/617 nm) staining was used to detect cells in distinct stages of cell death. These two 
stains can be used in parallel in this fashion, because they don’t have overlapping wavelength 
ranges. The concentration of the cell suspension was adjusted to 1×106 cells/mL. The L5178Y 
mouse T-cell lymphoma cell suspension was distributed into 0.5 mL aliquots (5×105 cells) to 
Eppendorf tubes. The mouse T-lymphoma cells were then incubated in the presence of the 
compounds for 1 h at 37˚C. In case of the Colo 320 cell line, the cell suspension was distributed 
to 24-well plate and incubated overnight at 37˚C in 5% CO2 incubator. On the following day, 
the medium was removed, and fresh medium was added to the cells containing the tested 
compounds. The incubation period for colonic adenocarcinoma cells in the presence of the 
compounds was 3 h. 12H-benzo[]phenothiazine M627 was used as positive control at the 
final concentration of 20 µM, which is a known early apoptosis inducer, whereas DMSO was 
used as solvent control (at 2 V/V%). The samples were washed in PBS and the harvested cells 
were centrifuged at 2000  g for 2 minutes. Fresh medium was added to the cells, followed by 
the overnight incubation of the plate at 37˚C, in 5% CO2 atmosphere. After the incubation 
period, the Colo 320 cells were removed gently from the wells using a cell scraper. Following 
this step, the apoptosis assay was carried out according to the „rapid” protocol of the kit, and 
the fluorescence was analyzed immediately using a ParTec CyFlow flow cytometer (Partec, 
Munster, Germany). 
Predictive in silico assay 
A preliminary in silico assay was performed using the freely accessible software packages 
OSIRIS Molecular Property Explorer (Actelion Pharmaceuticals, Allschwil, Switzerland) and 
PreADMET 2.0 (Yonsei University, Seoul, Republic of Korea) to predict the physico-
chemical and in vivo absorption properties of the tested compounds. OSIRIS works with a 
database of 2000-5000 drug molecules (depending on the model in question), while 
PreADMET 2.0 contains the experimentally measured physico-chemical attributes of more 
than 1 million molecules. The following properties of the tested compounds were assessed to 
verify their conformity with Lipinsky’s Rule of Five (RO5): molecular weight (M), number of 
hydrogen bond donors (n-OHNH), number of hydrogen bond acceptors (n-ON), base 10 
logarithm of the octanol/water partition coefficient (cLogP), base 10 logarithm of water 
solubility (logS; expressed as mol/L) and topological polar surface area of the molecules 
(TPSA). Additionally, the programs were used to predict the pharmacokinetic (i.e., ADME) 
properties of the tested compounds, such as the percentage of plasma protein binding (PPB%), 
permeability on different model systems of cellular monolayers (Caco-2, MDCK), percentage 
of human intestinal absorption (HIA%) and interaction with various cytochrome P450 
enzymes. To compare our data to clinically relevant anticancer agents, various, structurally 
and functionally different chemotherapeutic drugs (doxorubicin, gemcitabine, irinotecan, 
methotrexate, and 5-fluorouracil) were chosen as references. Additionally, a correlation-
regression analysis was performed with the aim of assessing the relationship between the 
measured fluorescence ratios (i.e. efflux pump inhibitory activity) on mouse T-lymphoma and 
colonic adenocarcinoma cells and selected physico-chemical properties (M, cLogP, logS and 
logTPSA). The statistical analyses were performed using Past 3.16 statistical software: p<0.05 
was considered statistically significant, furthermore the coefficient of determination (R2) was 
also calculated, which shows percentage variation in FAR values which is explained by the 
respective physico-chemical parameters. 
  
IV.  RESULTS 
Cytotoxicity assay 
The cyclic selenoanhydride (1) and the selenoesters 9-11 exerted remarkable cytotoxic 
activity on both the parental and multidrug resistant murine cell lines (0.94-3.97 µM and 0.43-
4.65 µM), the latter three compounds were proven to be cytotoxic in nanomolar range, the 
IC50 value for the most active selenoester (10) was 430 nM in MDR cells. Compounds 3 and 
6 also presented with strong cytotoxicity, but they exhibited their activity in concentrations 5-
40 times higher, than the previous four compounds. Selenoesters 9-11 were also toxic on non-
tumoral mouse embryonic fibroblast cells at low concentrations (IC50: 0.62-1.35 µM), while 
compounds 2 and 7 (IC50: 23.72 µM), 6 and 8 (IC50: 69.69 and 74.47 µM) exhibited toxic 
properties in similar concentrations. Compound 10 was moderately selective (SI=3.14), while 
the selenoanhydride showed excellent (SI≥ 25.19) selectivity towards the cancerous cell lines. 
The assays on human colonic adenocarcinoma cells showed that selenoesters 9-11 had strong 
cytotoxic effect on both the sensitive (Colo 205) and multidrug resistant colonic 
adenocarcinoma (Colo 320) cell lines (IC50: 1.19-5.48 µM and 0.35-0.96 µM, respectively), 
the IC50 value for the most active selenoester (9) was 350 nM in Colo 320 cells. It is worth 
noting that selenoesters 9 and 11 displayed moderate-strong selectivity (SI: 3.40-10.0) towards 
the Colo 320 cell line and colonic adenocarcinoma cells (SI: 4.2-14.40).  
The activity of the cyclic selenoanhydride and two other selenoesters (4 and 8) were 
similarly encouraging, as they did not show cytotoxic activity on the Colo 205 cell line, but 
exerted activity on the resistant cells. The IC50 values of cisplatin were 11.36-108.29-times 
higher than that of selenoesters 9-11 and the selenocompounds were 2.07-6.09-times more 
selective towards colonic adenocarcinoma cells. Similarly, selenocompounds 9-11 emerged 
as potent cytotoxic agents on A549 lung carcinoma cells (IC50: 5.91-15.22 µM), together with 
two other compounds (2 and 8) which were cytotoxic approximately at 50 µM. However, the 
compounds showed slight or no selectivity (0.09-1.95) in respect to lung adenocarcinoma/lung 
fibroblast cells. The reference compounds (12-15) did not have cytotoxic activity on any of 
the tested cell lines. 
Inhibition of the ABCB1 efflux pump 
Four derivatives (1, 9-11) out of the eleven compounds exhibited remarkable ABCB1 
inhibitory activity (the intracellular concentration of R123 was the highest) on the MDR mouse 
T-lymphoma and Colo 320 colonic adenocarcinoma cell lines at 20 µM concentration. The FAR 
quotients of the active compounds were 217.71-458.48% compared to the positive control’s 
(verapamil, 20 µM) activity. The two most active compounds (cyclic selenoanhydride 1 and 
selenoester 9) were more potent inhibitors of ABCB1 than verapamil in concentrations ten 
times lower (20 vs. 2 µM), with quotient values of 202.58% and 442.41%, respectively. 
Comparable results were observed on the ABCB1-overexpressing Colo 320 cells; the cyclic 
selenoanhydride 1 and selenoesters 9-11 were promising inhibitors of the efflux protein, 
outperforming verapamil (FAR=2.85) in 2 µM concentration (quotients ranging from 135.44-
401.05 %). The other compounds investigated in our study (selenoesters 2-8 and reference 
compounds 12-15) did not show efflux pump inhibitory activity similar to verapamil on either 
cell lines.  
  
Apoptosis assay 
The efficacy of the apoptosis-inducing properties of the selenocompounds was 
compared to 12H-benzo[]phenothiazine. The tested selenocompounds were effective 
apoptosis-inducers on murine cell lines. The cyclic selenoanhydride (1) and the selenoesters 9-
11 were the most noteworthy, compared to the positive control, when considering the total 
percentage of apoptotic events. The positive control only matched the activity of the 
abovementioned compounds at ten times higher concentrations (2 vs. 20 µM). In the experiment 
on multidrug resistant mouse T-lymphoma cells, compound 1 had excellent activity, as it 
induced early apoptosis in 32.2% of the gated cell population (77.67% overall). In addition, the 
selenoesters 9-11 were also effective, although their activity was predominantly detected as late 
apoptosis/necrosis inducers. The compounds exhibited comparable apoptosis inducing effects 
on the parental mouse T-lymphoma cells. However, it is of interest that compounds 10-11 were 
notably more effective on the susceptible parental cell line (apoptotic events in 39.01% vs. 
84.37% and 47.16% vs. 92.46% of the gated cell population, respectively). The roles of efflux 
transporters have been described in apoptosis evasion, mediated by dampening of the extrinsic 
apoptotic pathway and the stabilization of cell membrane; the inter-relatedness of 
overexpressed efflux pumps and programmed cell death may explain our observations in these 
experiments. Another possible explanation is the lower intracellular concentration of these 
compounds due to the operation of the ABCB1 efflux pump: while compounds 9-11 were all 
cytotoxic (IC50˂2 µM), thus contributing to their late apoptosis/necrosis inducing properties on 
murine cells, selenoester 9 was an effective efflux pump modulator at 2 µM concentration, 
while compounds 10-11 were only effective as EPIs at 20 µM. The fact that the compounds 
exhibited similar percentages of late apoptosis/necrosis on PAR cells, while compound 9 was 
disproportionally (2.8-3.9-times) more effective on MDR cells further validates this hypothesis.  
 
The compounds (1, 9-11) showed a similar activity profile for multidrug resistant (Colo 
320) human colon adenocarcinoma cells (apoptosis was induced in 64.6-80.5% of gated cell 
population overall). Comparing the results on all three cell lines, it can be observed that the 
cyclic selenoanhydride 1 was a potent inducer of early apoptosis (32.2-66.1%), while the active 
selenoesters (9-11) mainly induced late apoptosis or necrosis, which may be attributed to their 
strong cytotoxic properties. Considering our results, the selenocompounds exhibited more 
potent early apoptosis inducing effect in the human colonic adenocarcinoma system. Other 
selenocompounds (2-8) and reference compounds (12-15) did not have comparable apoptosis 
inducing properties. 
Predictive in silico assay 
The selenocompounds are in accordance with the evaluation criteria detailed in the thesis, 
regarding their physico-chemical properties, and they all complied with the Rule of Five 
without exception, as opposed to certain reference compounds (doxorubicin, methotrexate, 
irinotecan). The organoselenium compounds are expected to have excellent oral bioavailability 
(96.74-99.10%) and based on the predicted permeability on Caco-2 monolayers, the compounds 
have moderate penetration properties. The predicted plasma protein binding (PPB%) is nearly 
100% for all respective selenocompounds, which can be attributed to the presence of the 
selenium atom in the biologically active molecules. The tested selenium compounds should be 
inhibitors of the CYP2C9 enzyme and excluding compound 6, they are presumably substrates 
and inhibitors of the CYP3A4 enzyme, which may pose an issue, if these compounds were to 
be co-administered with anticancer drugs that are metabolized on these enzymes.  
The efflux pump inhibitory activity (logFAR) of the tested selenocompounds showed 
significant association with their base 10 logarithm of the octanol/water partition coefficients 
(cLogP), both in the case of the measured data on MDR mouse T-lymphoma (p=0.0034; 
R2=0.6934) and Colo 320 colonic adenocarcinoma cells (p=0.0198; R2=0.5117). The molecular 
weight, the base 10 logarithm of topological polar surface area and the base 10 logarithm of 
water solubility did not show relevant correlation with the fluorescence (logFAR) data. 
 
V.  DISCUSSION 
 
Malignant diseases present a significant public health burden, accounting for 8.2 million 
deaths and 14.1 million new cancer cases worldwide (according to the data of the WHO). Due 
to the ageing population in developed countries, the mortality rates related to cancer are 
expected to increase further. Hungary has the worst mortality rates of lung and colon cancer 
among EU member states. The goal of chemotherapy is the elimination or reduction of 
malignant cell mass and to improve the quality of life of the patient. The use of chemotherapy 
is complicated by its low bioavailability, disadvantageous side effects due to non-selective 
cytotoxic activity, in addition to the emergence of multidrug resistance, whereby tumors show 
resistance to chemotherapeutic agents of different structure and mechanism of action. The two 
mechanisms of MDR elucidated in this thesis are the overexpression of energy-dependent efflux 
pumps and failure of apoptosis induction. Considerable number of compounds have been 
described with the ability to inhibit the function of the ABCB1 efflux pump, an emerging 
therapeutic strategy of using chemosensitizers as adjuvants, reversing the MDR phenotype. 
Inorganic selenium salts and organoselenium compounds have been extensively studied for 
their anticancer activities. Organic compounds containing selenium are known modulators of 
the intracellular redox state of mammalian cells, therefore they may be effective and selective 
anticancer drugs, since neoplastic cells are thought to be sensitive to exogenous ROS. The 
present study focuses on the activity of novel organoselenium compounds as anticancer agents 
and their potency as MDR reversers with respect the epidemiology of cancer in Hungary. An 
additional aim was to establish structure-activity relationship for the selenocompounds. 
Considering our results, selenocompounds with specific structures showed favorable 
activity in all assays, while others presented with limited or no activity. The compounds that 
were chosen as references (12-15) had no activity in any of the experiments. In the cytotoxicity 
assays, the chemical variation of the alkyl chain directly bound to the selenium atom in the 
selenoesters was key in modulating anticancer efficacy. A methyl (9) or tert-butylketone-
substituent (10,11) was the most profitable for cytotoxic activity, in addition to the cyclic 
selenoanhydride (1). The substituents on the aromatic ring seem to be less important for the 
anticancer potency. In general, the selenocompounds were the least effective and selective on 
the A549 lung adenocarcinoma cells. The potency of the selenoesters 9-11 is further verified 
by the fact that they had IC50 values in the nanomolar range in many cases and showed SI values 
over 6, in respect to human adenocarcinoma cells. The selenoanhydride (1) presented with very 
high selectivity in murine cell lines (SI>20) and was not toxic on any of the non-tumoral cell 
lines. Results obtained from the rhodamine 123 accumulation studies are in concordance with 
those from the cytotoxicity assay.  
The 4-chlorophenyl-substituted methyl-ketone-substituted selenoester (9) was the most 
active compound (surpassing any other tested molecule in 2 µM concentration), followed by 
cyclic selenoanhydride and the two remaining acylmethyl-selenoesters (10,11), showing 
similarly potent ABCB1 inhibition at 20 µM. The efflux pump modulatory activity of 
selenoesters 2-8 was not comparable to the effect of verapamil, due to the variable side chains 
in their structures. It is also important to note that the lipophilicity of the compounds influenced 
ABCB1 modulation, as the cLogP values showed significant (p<0.05) correlation with the 
calculated FAR values.  
In the apoptosis assay, the abovementioned four compounds (1, 9-11) induced apoptosis 
in 39.01-97.32% of the tested murine cells and 64.6-71.4% of human cells, respectively. 
However, the selenoanhydride (1) was the most effective inducer of early apoptosis (around 
one-third of the gated cell population of mouse T-lymphoma cells and two-thirds of the colonic 
adenocarcinoma cells), surpassing the activity of the positive control (M627) used in the 
experiments. On the other hand, the acylmethyl-selenoesters also had pronounced toxic activity, 
which predominantly presented as necrosis (up to 85.80% in murine cells). This distinction in 
the activity profiles is relevant because early apoptosis is the advantageous type of cell death 
for chemotherapy-treated malignant cells, as collateral damage will not occur in adjacent cells 
due to the release of inflammatory mediators compared to necrotic cell death processes. The 
remaining selenoesters (2-8) had slight or no capacity to induce apoptosis, although the human 
colonic adenocarcinoma cell line showed to be more sensitive to the treatment with the 
selenocompounds. 
Organic compounds contacting chalcogenic elements (S, Se, Te) recently received 
substantial interest in experimental oncopharmacology. The literature suggests that the most 
active member of this group is tellurium (Te); but it has been shown that the Te-containing 
compounds are highly toxic and do not possess adequate selectivity. The advantage of Se-
compounds is that they affect various cellular redox mechanisms and signal transduction 
pathways, which makes them especially appealing. The reference compound 12, which showed 
no activity in any of the experiments, is the oxygen-isoster of the cyclic selenoanhydride, which 
suggests the significant role of Se atom for the activity of these organic molecules. The exact 
molecular mechanism of these compounds is yet to be described. According to the previous 
studies and hypotheses of Domínguez-Álvarez et al., it is proposed that the activity of 
organoselenium derivatives lies in the hydrolysis of the selenoester group. This breakdown 
allows the liberation of selenium anions to the medium, allowing for these particles to take part 
in oxidation-reduction reactions due to the charged selenium atom. In other words, it is 
suggested that the novel selenoesters act as prodrugs that make the transport of the molecules 
possible through the cell cytoplasm. Inside the cells, the breakdown of the carrier molecule 
liberates the active ionic chemical forms of selenium with cytotoxic properties in cells. The 
inclusion of electron withdrawing groups, like a ketone or a carboxylic acid is thought to 
facilitate the breakdown for stabilizing the resulting fragments. However, it is not desirable to 
design derivatives whose breakdown occurs before the arrival of the compound to the 
cytoplasm of the target cells. In this case, the ionic species generated in the extracellular 
hydrolysis would not pass the cell membrane due to their hydrophilic properties. The rationale 
behind the activity of the cyclic selenoanhydride is presumably like those of compounds 9-11, 
however, the degradation mechanisms and kinetics of this compound should be different, as it 
contains the Se atom in a five-member ring system. Also, it is not clear whether the tested 
compounds are competitive inhibitors of the efflux pump or bind to a specific domain of the 
ABCB1 transporter. 
 
Overall, four compounds were identified as promising candidates for further studies: the 
cyclic selenoanhydride (1; benzo[c]selenophene-1,3-dione), and the selenoesters 9-11. All 
respective compounds exhibited remarkable anticancer and multidrug resistance reversing 
(ABCB1 pump-modulating and apoptosis inducing) properties. Considering the predicted data 
from the in silico assays, these four compounds show attractive properties for good in vivo 
bioavailability and potential for transitioning from the pre-clinical to clinical study phase (as 
presented by their conformity to the RO5 and predicted HIA percentages). As for future 
perspectives, the derivatization and synthesis of novel structural variants of these compounds 
are warranted. In addition, as there is abundant literature regarding various selenium 
compounds co-administered with various chemotherapeutic drugs, the survey of these agents 
in vitro could shed some light about their potency as combinational drugs. 
 
VI. NEW FINDINGS 
 
a. Selenocompounds as cytotoxic agents: Three selenoesters with ketone-containing alkyl 
groups showed potent cytotoxic activity on mouse T-lymphoma, human colon adenocarcinoma 
and human lung adenocarcinoma cell lines with IC50 values in the nanomolar range. The cyclic 
selenoanhydride was highly active and selective towards malignant murine cell lines.  
b. Selenocompounds as efflux pump inhibitors: The cyclic selenoanhydride and three 
selenoesters with ketone-containing alkyl groups showed potent efflux pump modulatory 
effects in the ABCB1-overexpressing subline of mouse T-lymphoma and human colon 
adenocarcinoma cell lines. The 4-chlorophenyl-substitution was the most beneficial for 
ABCB1-inhibiting activity on both murine and human cell lines.  
c. Selenocompounds as apoptosis inducers: The cyclic selenoanhydride was an effective 
inducer of early apoptosis, while the selenoesters with ketone-containing alkyl groups 
predominantly induced late apoptosis/necrosis in parental and multidrug resistant mouse T-
lymphoma and MDR human colon adenocarcinoma cell lines.  
d. Prediction of ADME properties of the selenocompounds by in silico methods: All 
organoselenium compounds compiled with Lipinsky’s Rule of Five and they are expected to 
have moderate intestinal penetration properties, very strong plasma protein binding and 
excellent oral bioavailability. The results suggest a link between the lipophilicity and efflux 
pump modulatory activity of the compounds.  
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